

# Recombinant Human VEGF<sub>165</sub>

**Description:** Human Vascular Endothelial Growth Factor VEGF<sub>165</sub>, a 23 kDa protein consisting of 165 amino acid residues, is produced as a homodimer. VEGF is a polypeptide growth factor and a member of the platelet-derived growth factor family. It is a specific mitogen for vascular endothelial cells and a strong angiogenic factor *in vivo*. Two high-affinity tyrosine kinase receptors for VEGF<sub>165</sub> have been identified, VEGFR-1 (FLT-1), and VEGFR-2 (KDR). Consistent with the endothelial cell-specific action of VEGF<sub>165</sub>, expression of both receptor genes has been found predominantly but not exclusively on endothelial cells. Expression of VEGFR-1 was also found on human monocytes, neutrophils (PMNs), bovine brain pericytes and villous and extravillous trophoblasts. In addition to its action as a mitogen it is a potent vascular permeability factor (VPF) *in vivo*. VEGF<sub>165</sub> is also a chemoattractant molecule for monocytes and endothelial cells. 5 different proteins are generated by differential splicing: VEGF<sub>121</sub>, VEGF<sub>145</sub>, VEGF<sub>165</sub>, VEGF<sub>189</sub> and VEGF<sub>206</sub>. The most abundant form is VEGF<sub>165</sub>. Whereas VEGF<sub>121</sub> and VEGF<sub>165</sub> are secreted proteins, VEGF<sub>145</sub>, VEGF<sub>189</sub> and VEGF<sub>206</sub> are strongly cell-associated. The isoforms VEGF<sub>145</sub>, VEGF<sub>165</sub> and VEGF<sub>189</sub> bind to heparin with high affinity. VEGF<sub>165</sub> is apparently a homo-dimer, but preparations of VEGF<sub>165</sub> show some heterogeneity on SDS gels, depending on the secretion of different glycosylation patterns. All dimeric forms have similar biological activities but their bio-availability is very different. There is good evidence that heterodimeric molecules between the different isoforms also exists and that different cells and tissues express different VEGF isoforms. The other members of this increasing growth factor family are VEGF-B, -C, -D and -E. Another member is the Placenta growth factor PlGF.

<b>Source:</b>	Insect cells
<b>Molecular Weight:</b>	45 kDa
<b>Purity:</b>	> 90%, by SDS-PAGE and visualized by silver stain
<b>Endotoxin level:</b>	< 0.1 ng per µg of VEGF
<b>Stabilizer:</b>	none
<b>Buffer:</b>	50 mM acetic acid
<b>Formulation:</b>	lyophilized

**Biological Activity:** The ED<sub>50</sub> for stimulation of <sup>3</sup>H-thymidine incorporation and cell proliferation by human umbilical vein endothelial cells for VEGF<sub>165</sub> has been determined to be in the range of 1-2 ng/ml.

**Reconstitution:** The lyophilized VEGF<sub>165</sub> is soluble in water and most aqueous buffers. The lyophilized VEGF<sub>165</sub> should be reconstituted in PBS or medium containing at least 0.1% human or bovine serum albumin to a concentration not lower than 50 µg/ml.

**Stability:** Lyophilized samples are stable for greater than six months at -20°C to -70°C. Reconstituted VEGF<sub>165</sub> should be stored in working aliquots at -20°C. **Avoid repeated freeze-thaw cycles!**

**Usage:** VEGF<sub>165</sub> is offered for research use. Not for drug use. **Not for human use!**

<b>Catalogue number:</b> 300-036	<b>Size:</b> 20 µg
	<b>Range:</b> 1-10 ng/ml

Literature: [Breier et al., Dev 114:521, 1992; Fiebig et al., Eur J Biochem 211:19, 1993; Flamme et al., Dev Biol 162:699, 1995; Kremer et al., Cancer Res 57:3852, 1997]

**\*\*Please note: always centrifuge vials before opening!\*\***